Home Lymphoma HCT shows curative potential in high-risk T-cell lymphoma

HCT shows curative potential in high-risk T-cell lymphoma


December 08, 2020

1 min watch



Mehta-Shah N, et al. Abstract 41. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Barta reports consulting for Monsanto; research funding from Seattle Genetics; and receiving honoraria from Acrotech, Atara, Janssen, Pfizer and Seattle Genetics.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Allogeneic hematopoietic transplantation yielded durable disease control for patients with relapsed or refractory or otherwise high-risk T-cell lymphoma, according to a presentation at ASH Annual Meeting and Exposition.

The study, which is the largest retrospective analysis of HCT in T-cell lymphoma, included 500 patients across 12 centers with a variety of T-cell lymphomas, Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, told Healio in a video interview.

The treatment-related mortality rate was 11.2%, which Barta said is “pretty amazing.” The 2-year OS and PFS rate following allogeneic hematopoietic transplantation were 59.1% and 45.8%, and the 5-year OS and PFS rate were 50.8% (95%CI, 46.1-55.3%) and 39.4%, according to the abstract.

“Over the last 2 decades, we’ve been much better in A, typing our patients and finding better donors and B, managing infections and graph host disease so supportive care has improved,” Barta said. “This [study] underpins the allogenic transplant as a very reasonable option for patients specifically who achieved a complete response to salvage therapy. It provides us great information and numbers to discuss this option with our patients – in that respect, it’s a very important study.”


This site uses Akismet to reduce spam. Learn how your comment data is processed.